Varian Manufactures Halcyon Radiotherapy Systems in Germany for the First Time

Siemens HealthineersVarian, a Siemens Healthineers company, manufactures the first Halcyon radiotherapy system at its Kemnath site. Siemens Healthineers built a completely new production line at the plant and expanded its research and development team. With the acquisition of Varian, these are once again part of the Siemens Healthineers product portfolio. Systems for the German, European and US markets are manufactured in Kemnath. The first Halcyon from Kemnath goes to Curavid Radiotherapy and Radiology in Lübeck. Siemens Healthineers announced in February 2022 that it would invest EUR 60 million in the Kemnath production site and create 50 new jobs. The expansion of the production to include radiotherapy devices is part of this investment.

"We want to further expand the production of radiotherapy systems in Kemnath and increase the quantities. We also want to increase the vertical integration of the Halcyon system by producing more individual parts here in the plant," said Michael Braunreuther, head of the Kemnath site at Siemens Healthineers. "The expansion of our portfolio here in Kemnath is a further commitment to Germany as a location for innovation."

Radiotherapy is one of the most important methods of modern cancer therapy and is now used in more than half of all cancer treatments. The radiotherapy devices, so-called linear accelerators, are part of the product portfolio of Varian, now a Siemens Healthineers company. Linear accelerators are used both in the outpatient sector and in hospitals for the targeted treatment of cancer. The Halcyon system from Varian is one of the most technically innovative accelerator systems on the market. Siemens Healthineers built another production site for these systems in Kemnath. A second production site is located in Beijing. Until 2012, Siemens Healthineers manufactured radiotherapy systems in Kemnath. Parts of the infrastructure, such as the radiation-proof test cabins, are still available and can be used to test the new Varian systems. The production of radiotherapy systems complements the existing portfolio at the site. The Kemnath plant in the Oberpfalz region was established in 1962. It has grown since then from a purely contract-based manufacturer to a Center of Competence for mechatronics that covers large parts of the Siemens Healthineers product range. The components developed and manufactured in Kemnath include C-arms for angiography systems in addition to tables for MRI units and components for analytical systems used in lab diagnostics. In the future, tables for the TrueBeam radiotherapy system will also be manufactured here.

About Siemens Healthineers

Siemens Healthineers AG (listed in Frankfurt, Germany: SHL) pioneers breakthroughs in healthcare. For everyone. Everywhere. As a leading medical technology company headquartered in Erlangen, Germany, Siemens Healthineers and its regional companies are continuously developing their product and service portfolio, with AI-supported applications and digital offerings that play an increasingly important role in the next generation of medical technology. These new applications will enhance the company's foundation in in-vitro diagnostics, image-guided therapy, in-vivo diagnostics, and innovative cancer care. Siemens Healthineers also provides a range of services and solutions to enhance healthcare providers’ ability to provide high-quality, efficient care. In fiscal 2022, which ended on September 30, 2022, Siemens Healthineers, which has approximately 69,500 employees worldwide, generated revenue of around €21.7 billion and adjusted EBIT of almost €3.7 billion.

Most Popular Now

AI Tool Helps Predict Relapse of Pediatr…

Artificial intelligence (AI) shows tremendous promise for analyzing vast medical imaging datasets and identifying patterns that may be missed by human observers. AI-assisted interpretation of brain scans may help improve...

Detecting Lung Cancer 4 Months Earlier a…

GPs may soon be able to identify patients with an increased risk of lung cancer up to 4 months earlier than is currently the case. The GP should be able...

Infectious Disease Surveillance Platform…

The Biothreats Emergence, Analysis and Communications Network (BEACON) leverages advanced artificial intelligence (AI), large language models (LLMs) and a network of globally based experts to rapidly collect, analyze, and disseminate...

Children's Health Ireland to Transf…

Healthcare teams responsible for paediatric care in Ireland are to save significant time in accessing important diagnostic imaging and reports, with the help of a new agreement with medical imaging...

NHS, Councils, and Housing could Share N…

A new technology partnership formally announced, could help NHS, local government, and housing organisations collaborate to create an unprecedented understanding of the risks and needs of people in their care...

AI-Powered Analysis of Stent Healing

Each year, more than three million people worldwide are treated with stents to open blocked blood vessels caused by heart disease. However, monitoring the healing process after implantation remains a...

Right Patient, Right Dose, Right Time

While artificial intelligence (AI) has shown promising potential, much of its use has remained theoretical or retrospective. Turning its potential into real-world healthcare outcomes, researchers at the Yong Loo Lin...

An AI Tool Grounded in Evidence-Based Me…

A powerful clinical artificial intelligence tool developed by University at Buffalo biomedical informatics researchers has demonstrated remarkable accuracy on all three parts of the United States Medical Licensing Exam (Step...

AXREM and BHTA Name Highland as 'Fu…

Hosted by trade associations AXREM and the British Healthcare Trades Association (BHTA), 'The Future of MedTech - Innovating for Tomorrow', will allow delegates to engage with speakers from the government...